Schizophrenia – Unmet Need – Unmet Need – Cognitive Impairment Associated with Schizophrenia (US/EU)
CIAS (e.g., impaired attention / vigilance, memory, and/or executive function) negatively impacts patients’ daily activities, occupational and social functioning, and adherence to antipsychotic treatment. Although the schizophrenia drug market is crowded, no drugs are approved specifically to treat CIAS. Psychiatrists may prescribe either an adjunctive drug treatment (e.g., cognition-enhancing agent) or a nonpharmacological therapy (e.g., cognitive remediation) or both over a baseline antipsychotic regimen (for positive symptoms of schizophrenia); however, no therapy has demonstrated consistent efficacy in improving cognition in schizophrenia. Although the late-phase pipeline for CIAS is sparse, Boehringer Ingelheim’s iclepertin has had promising Phase 2 results and has received FDA breakthrough therapy designation for CIAS. Great unmet need and commercial opportunity exist for an efficacious and safe therapy in this underserved schizophrenia segment.
Questions answered
- Which clinical / nonclinical attributes for a therapy influence psychiatrists’ treatment decisions in CIAS?
- How do psychiatrists rate the performance of key current therapies on treatment drivers and goals for CIAS?
- What is the relative level of need for improved treatment options in CIAS and related diseases, and in other schizophrenia symptom domains? What are the prevailing areas of unmet need in CIAS?
- How do psychiatrists’ preference and likelihood to prescribe vary across the set of user-defined Target Product Profiles in CIAS?
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European psychiatrists fielded in May 2024
Key companies: Otsuka Pharmaceutical, Lundbeck, Boehringer Ingelheim, Johnson & Johnson Innovative Medicine, Novartis, AbbVie, Eisai, Teva
Key drugs: Aripiprazole, risperidone, rivastigmine, memantine, donepezil, modafinil
